Genzyme, Isis Partner On Lipid Lowering Treatment Based On Antisense Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme calls mipomersen, currently in Phase III, a blockbuster after gaining rights in potential $1.9 billion deal.
You may also be interested in...
Genzyme/Isis Build Simple, No Fuss Case For Weekly Cholesterol Injectable Kynamro
Genzyme and Isis are playing up mipomersen’s intrinsic qualities as they prepare to go head-to-head against Aegerion’s Juxtapid in the small homozygous familial hypercholesterolemia market. Kynamro also will carry a price tag that is $119,000 less than Juxtapid’s.
Genzyme/Isis Gear Up For Long-awaited Kynamro Launch
Genzyme said it is ready to deliver product, but complying with the REMS that helped pave the way for approval is a time-limiting factor for launching the familial hypercholesterolemia drug. Drug will be priced at $176,000 per year, significantly lower than Aegerion’s competing Juxtapid.
EU's CHMP Clears Selincro And Perjeta, Rejects Kynamro And Fanaptum
Europe's top scientific advisory panel backed Lundbeck's alcoholism therapy Selincro (nalmefene) and Roche's next-generation breast cancer therapy Perjeta (pertuzumab) but rejected Genzyme/Isis' antisense therapy Kynamro (mipomersen) and Vanda's Fanaptum (oral iloperidone).